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Abstract Head and neck cancer (HNC) is a heterogenous
and complex entity including diverse anatomical sites and a
variety of tumor types displaying unique characteristics and
different etilogies. Both environmental and genetic factors
play a role in the development of the disease, but the
underlying mechanism is still far from clear. Previous
studies suggest that alterations in the genes acting in
cellular signal pathways may contribute to head and neck
carcinogenesis. In cancer, DNA methylation patterns
display specific aberrations even in the early and
precancerous stages and may confer susceptibility to
further genetic or epigenetic changes. Silencing of the
genes by hypermethylation or induction of oncogenes by
promoter hypomethylation are frequent mechanisms in
different types of cancer and achieve increasing diag-
nostic and therapeutic importance since the changes are
reversible. Therefore, methylation analysis may provide
promising clinical applications, including the develop-
ment of new biomarkers and prediction of the therapeutic
response or prognosis. In this review, we aimed to
analyze the available information indicating a role for
the epigenetic changes in HNC.
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Introduction
Head and neck cancer (HNC) is a highly heterogenous
group of malignant diseases and the sixth most frequently
observed cancer type in developing countries (Crowe et al.
2002; Ohshima et al. 2005). It reveals different combina-
tions of various sites and disease types which result from
sequential genetic changes in multiple intracellular pathways
and inherent viral infections. HNC displays serial dysplastic
alterations before acquiring invasive characteristics. Tobacco
and/or alcohol use are the main etiological factors and play an
important role in oral cavity, pharynx, and larynx cancer
(Ohshima et al. 2005). Acute laryngitis which can be caused
by chronic irritation, inhalation of irritants, viral infections,
or allergic reactions may also increase the risk of cancer
development (Kumar et al. 2000). The prognosis of the
disease varies according to tumor size, local invasion,
histology, and grade as well as ethnic origin. These diverse
varieties reflect the versatile pathogenesis of the disease.
Identification of novel therapeutic targets and new and
specific biomarkers for the early detection of HNC could
greatly increase the survival rate and might also help as
prognostic indicators.
Head and neck carcinogenesis is a multistep and
multifactorial complex mechanism containing a variety of
genetic and epigenetic abnormalities in DNA repair, signal
transduction, apoptosis, angiogenesis, proliferation, differ-
entiation, and cell cycle regulation (Scully et al. 2000). In
recent years, the role of epigenetic alterations have been
increasingly recognized. Changes in the methylation patterns
are one of the most frequent events in human tumors (Jones
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and Baylin 2002). Two types of methylation changes are
usually observed : Hypermethylation of the CpG islands and
global hypomethylation in a variety of tumors. DNA
hypomethylation has been associated with the activation of
oncogenes and chromosomal instability leading to over-
expression of the oncogenes, while DNA hypermethylation
is associated with the repression of tumor suppressor genes
(TSG) and genomic instability. DNA methylation also plays
an important role in tumor initiation and progression (Jones
and Baylin 2002; Momparler and Bovenzi 2000). Thus, gene
silencing by hypermethylation is an important mechanism
that has great promise for therapy and for the discovery of
new biomarkers. Hovewer, the information on the frequency
and specificity of methylation changes is still insufficient. It
presents a challenge to identify crucial genes that are
susceptible to methylation-induced silencing and are directly
associated with the development of HNC. Since HNC is a
heterogenous disease, the methylation status may vary
according to clinical characteristics and environmental and
genetic factors such as anatomic involvement of tumor
(Dikshit et al. 2007; Azarschab et al. 2003), human
papilloma virus (HPV) positivity (Bennett et al. 2010;
Richards et al. 2009), smoking (Sharma et al. 2010),
microsatellite instability (MSI) (Zuo et al. 2009; Demokan
et al. 2006; Sengupta et al. 2007; Liu et al. 2003a, b, 2002),
and geographic location (Li et al. 2003a, b; Ayadi et al.
2008). Therefore, analysis of the epigenetic changes in genes
playing important roles in these vital molecular mechanisms
is crucial in order to understand the molecular biology of
head and neck carcinogenesis.
Genetic evidence indicates that the majority of squamous
HNC originate from hyperplastic fields characterized by
higher numbers of proliferating cells and clonal selection
(Rubin 2011; Tabor et al. 2002). Almost two thirds of the
tumor recurrences following resection occur in these
regions (Tabor et al. 2004; Ha and Califano 2003). Clonal
selection, divergence, and expression are the basic charac-
teristics of the field development. Molecular evidence
including cells harboring mutations of the TSG and recent
data on p53 mutations support the field cancerization
theory. The presence of cells with p53 gene mutations in
these fields have also been shown in HNC (Tabor et al.
2001). The genetic changes characterizing these regions can
be used to identify individuals at risk of developing cancer
(Dakubo et al. 2007). Furthermore, methylation in noncan-
cerous tissues is now considered as a marker for potential
cancer risk and previous exposure to certain carcinogenic
factors (Nakajima et al. 2008). Knowledge of the methylation
status in these regions may enable intervention by using
demethylating agents as chemopreventive means (Dakubo et
al. 2007). An epigenetic field effect has been first described
by increased aberrant methylation in normal tissue from
patients with liver cancer (Kondo et al. 2000). Later studies
have unequivocally shown the presence of an epigenetic field
for cancerization (Ushijima 2007). Recently, the presence of
an epigenetic field for cancerization has also been shown in
colon (Shen et al. 2005), breast (Yan et al. 2006), and renal
(Arai et al. 2006) cancers.
Recent advances in technology make it possible to analyze
DNA methylation by highly sensitive and quantitative
methods. For DNAmethylation analysis, a variety of different
methodologies have been used, almost all of which rely on
three different approaches for treating DNA: the action of
methylation-specific endonucleases, bisulfite modification of
unmethylated cytosines, or immunoprecipitation (IP) of the
methylated DNA fragments. Combination of these initial
steps with different detection techniques for analysis
have resulted in various analytical methods to investigate
candidate genes or to study global DNA methylation.
The main methodologies used for methylation analysis
are summarized in Table 1. Several techniques initially
confined to smaller regions of the genome have now been
extended to perform analysis of the whole genome. New
high-throughput methodologies provide information to
characterize methylated sequences at single-base resolution
on a genome-wide scale.
Recent studies have shown that hypermethylation of
some TSG may be a valuable biomarker (Kim et al. 2006;
Demokan et al. 2010; Kaur et al. 2010; Pattani et al. 2010)
in different cancer types. Furthermore, results of clinical
Table 1 The main methodologies used in DNA methylation analysis
Sequence-specific methylation
Quantitative methylation-specific PCR (QMSP)
Methylation-sensitive restriction enzyme analysis
Sensitive restriction-multiplex PCR
Combined bisulfite restriction analysis (COBRA)
Bisulfite sequencing
Pyrosequencing
Multiplex ligation-dependent probe amplification (MLPA)
Mass array analysis
Global methylation
Restriction landmark genomic scanning (RGLS)
Arbitrarily primed methylation-sensitive PCR (AP-MSP)
Methylated CpG island recovery assay (MIRA)
Differential methylation hybridization (DMH)
Analysis of intermethylated sites (AIMS)
Methylated DNA immunoprecipitation (MeDIP)
Whole-genome shotgun bisulfite sequencing (WGSBS)
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studies using DNA methyltransferase and histone deacety-
lase inhibitors indicate the potential of epigenetic therapeu-
tics in clinical oncology (Ren et al. 2011; Wagner et al.
2010). The epigenetic changes may help to predict the
prognosis and identify individuals who may benefit from
the therapy with demethylating agents (Issa et al. 2004).
In this review, we aimed to summarize the present state
of knowledge in head and neck carcinogenesis by analyzing
the studies investigating the relationship between methyla-
tion and HNC. The publications in the literature were
retrieved by literature and keyword search using the ISI,
PubMed, and Scopus databases to identify the studies
relevant to this review. Citations in these publications were
also evaluated for their relevance.
Data from analysis of tumor suppressor gene panels
In recent years, most studies have focused on the analysis
of promoter methylation of TSG panels playing a role in
vital cellular mechanisms via the candidate gene strategy
approach (Table 2). In a study among the North American
population (Demokan et al. 2010), KIF1A and EDNRB
genes were highly methylated (97% and 98%, respectively)
in the primary tumor tissue and salivary rinse samples from
patients with squamous cell carcinoma, while normal
salivary and normal mucosal samples were minimally
methylated. A significant association between KIF1A
methylation and tumor site was reported. Kaur et al.
(2010) found high methylation levels of the KIF1A,
EDNRB, DCC, and p16 genes in Indian patients with oral
squamous cell carcinoma (OSCC) and Pattani et al. (2010)
have shown that, in salivary samples from patients with
premalignant or malignant oral cavity lesions, promoter
hypermethylation of the KIF1A and EDNRB genes was
associated with malignancy. The endothelin receptor type
B (EDNRB) is a G protein-coupled receptor which
activates a phosphatidylinositol–calcium second messen-
ger system (Smollich and Wülfing 2008). The kinesin
family member 1A (KIF1A) gene encodes a protein that is
a microtubule-dependent molecular motor involved in
important intracellular functions such as organelle transport
and cell division (Okada et al. 1995).
We have evaluated the epigenetic changes specific to
head and neck squamous cell carcinoma (HNSCC) by
investigating promoter hypermethylation of a panel of 24
TSG via candidate gene approach in a recent study
(Yalniz et al. 2011). CHFR, RARβ, DAPK1, and RASFF1A
genes were found to be the most frequently methylated
genes in HNC tumor tissue by methylation-specific
multiplex ligation-dependent probe amplification. A further
collaborative study analyzing a panel of 22 genes confirmed
these findings and found that the RARβ, APC, and
CHFR genes were frequently hypermethylated in HNC
(Chen et al. 2007).
In another study, six genes were analyzed in patients
with HNSCC treated by radiotherapy (de Schutter et al.
2009). The MGMT and TIMP3 genes displayed higher
methylation rates. Promoter hypermethylation of the TIMP3
and CDH1 genes were significantly associated with better
locoregional control (LRC) and overall survival (OS) or
disease-free survival (DFS). TIMP3 methylation highly
correlated with DAPK methylation, indicating a very strong
functional association between these two genes (Nayak et
al. 2007). In other gene panel studies, methylation of the
TIMP3, CDH1, p16, MGMT, DAPK, and RASSF1 genes
were observed in HNSCC tumors and paired saliva samples
(Righini et al. 2007; Hasegawa et al. 2002; Rosas et al.
2001; Sanchez-Cespedes et al. 2000). A study analyzing
promoter methylation of 15 candidate genes (Steinmann et
al. 2009) in tumors and matched normal tissue from
patients with HNSCC has shown that methylation of the
p16, MGMT, DAPK, RARβ, hMLH1, CDH1, RASSF2,
RASSF5, and MST1 genes was significantly more frequent
in the tumors than the normal tissue (Steinmann et al.
2009). The hMLH1 (Puri et al. 2005), RARβ (Maruya et al.
2004), p16, and MGMT (Puri et al. 2005; Maruya et al.
2004) genes have also been found to be frequently
methylated in HNSCC. The higher increased methylation
of the TSG is usually associated with advanced tumor
stages and undifferentiated HNSCC. This has been primarily
shown for the p16 and RASSF5 genes (Steinmann et al.
2009). In the same study, RASSF4 gene methylation was
more frequent in patients with advanced tumor stage and
recurrent HNSCC than patients without relapse. Higher
methylation of the p16, RARβ, and RASSF1 genes was also
reported in a study in which matched normal samples were
not available (Okami et al. 2005).
In a study investigating three TSG functioning in
carcinogen metabolism (CYP1A1, CYP2A13, and GSTM1),
the genes were found to be moderately (27.4–58.1%)
methylated in the tumors, while methylation levels in
normal tissue were much lower. A significant correlation
was reported between smoking and the methylation status
of the CYP1A1 and CYP2A13 genes (Sharma et al. 2010).
Hypermethylation of the hMLH1 gene, which plays an
important role in DNA mismatch repair, has been found to
be significantly associated with decreased hMLH1 protein
expression, MSI, and decreased cause-specific survival for
HNSCC patients in various studies (Zuo et al. 2009;
Demokan et al. 2006; Sengupta et al. 2007; Liu et al.
2003a, b, 2002). Methylation of both hMLH1 and hMSH2
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genes may have an important role in oral carcinogenesis
and have been associated with the susceptibility for oral
malignancies (Czerninski et al. 2009).
Biomarkers predicting clinical response, tumor recurrence,
or patient survival are not available for many cancer types,
particularly for oral and pharyngeal cancer. Taioli et al. (2009)
have studied the methylation of a panel of TSG in order to
identify a possible correlation with survival and recurrence
rates in patients with oral or pharyngeal cancer. MGMT
promoter methylation was inversely associated with poor OS
and DFS, indicating that MGMT promoter methylation may
act as a possible prognostic biomarker for oral and
pharyngeal cancer (Taioli et al. 2009). In oral epithelial
dysplasia that transforms to OSCC, p16 methylation may act
as a candidate biomarker of malignant transformation,
whereas methylation of the MGMT, CYGB, and CCNA1
genes are not associated with malignancy (Hall et al. 2008).
In oral carcinomas, methylation of the p16 and MGMT genes
are frequently observed as an early event (Kato et al. 2006).
Promoter hypermethylation of the p16, p15, hMLH1,MGMT,
and CDH1 genes has been reported in OSCC (Viswanathan
et al. 2003). The Ras/PI3K/AKT pathway is a major
mechanism associated with radioresistance in OSCC. A
study investigating four genes (RASSF1A, RASSF2A, PTEN,
and HIN-1) in this pathway revealed that RASSF1A and
RASSF2A methylation were more frequent in the tumors and
significantly associated with poor DFS (Huang et al. 2009).
Methylation of CCNA1, CYGB, and p16 genes has also been
correlated with the clinicopathological parameters in oral
cancer (Shaw et al. 2006). In OSCC, different levels of
methylation have been reported for the p16, p15, p14, DCC,
DAPK, MINT1, MINT2, MINT27, and MINT31 gene
promoters and DCC methylation was associated with bone
invasion of gingival tumors, invasiveness, and reduced
survival (Ogi et al. 2002). Aberrant methylation of the
p14, p15, and p16 gene promoters has been reported in
HNSCC (Weber et al. 2002), oral precancerous lesions
(Takeshima et al. 2008), oral carcinomas (Sailasree et al.
2008; Yeh et al. 2003; Shintani et al. 2001), and salivary
gland carcinomas (Nishimine et al. 2003). When normal
tissue and benign and malignant salivary gland tumors
were compared, significantly higher methylation of the
APC, RARβ, MINT1, PGP9.5, and TIMP3 genes were
observed in salivary duct carcinoma (Durr et al. 2010). In
adenoid cystic carcinomas of the salivary gland, p16,
RASSF1A, and DAPK gene methylation is also a common
event (Li et al. 2005).
In patients with laryngeal and hypopharyngeal cancers,
promoter methylation of the p16, MGMT, DAPK, and
CDH1 genes are observed frequently (Dikshit et al. 2007;
Azarschab et al. 2003). For tumors in the oropharynx, a
statistically significant association between hypermethyla-
tion of the DAPK1 gene and risk of lymph node metastases
has been reported, and significant evidence indicate an
association between hypermethylation of the ADAM23 gene
and advanced tumor stage in larynx cancer (Calmon et al.
2007).
In a study investigating the methylation status of
candidate TSG in surgical margins as a predictor of local
recurrence in HNSCC, it has been shown that analysis of
the CDKN2A, CCNA1, and DCC genes in the surgical
margins by quantitative methylation-specific PCR (QMSP)
can correctly predict local recurrences in HNSCC (Tan et al.
2008). Using candidate gene and discovery approaches, 21
genes were investigated in HNSCC and normal tissue
samples. p16, MINT31, and RASSF1A gene methylation
were detected only in HNSCC but not in the controls
(Carvalho et al. 2008).
Data from mRNA expression array studies
Recently, studies investigating novel methylated TSG
specific to the tumor types have made use of mRNA
expression arrays to analyze more than 40,000 genetic
regions on a single platform via pharmacological unmasking
and discovery approaches (Yamashita et al. 2002; Tokumaru
et al. 2004).
After bisulfite sequencing, rapid subtractive hybridization,
and microarray analysis in order to determine genes that are
induced to reexpression by the demethylating agent 5-aza-2′-
deoxycytidine in HNSCC cell lines, 35 out of 78 genes were
selected and only 3 of these (CRABP2, MX1, and SLC15A3)
were verified by QMSP (Calmon et al. 2009). After
methylation-specific PCR (MSP) analysis, CRABP2 and
MX1 genes were highly methylated in primary HNSCC
compared with lymphocytes from a healthy cohort. In
addition, lack of the CRABP2 protein was associated with
poor survival rates, indicating that CRABP2 expression may
be a potential prognostic biomarker for patients with HNSCC.
In a study, PGP9.5, CCNA1, bone morphogenetic
protein 2A (BMP2A), metallothionein 1G (MT1G), and
neuromedin U (NmU) genes were highly methylated and
CCNA1 hypermethylation displayed an inverse correlation
with p53 mutations (Tokumaru et al. 2004).
Methylation of the Nischarin (NISCH), p21-activated
protein kinase 3 (PAK3), KIF1A, and OGDHL genes has
been reported in 8–52% of the patients with HNC, whereas
no methylation was observed in the normal cohort (Hoque
et al. 2008).
Global methylation
A recent study indicated the involvement of global DNA
hypermethylation in the pathogenesis of HNSCC (Worsham
136 Clin Epigenet (2011) 2:123–150
et al. 2010). Using DNA IP and Affymetrix whole-genome
tiling arrays, 231 new and previously unreported genes out
of 1,143 cancer genes on the array were identified via the
whole-genome methylation approach.
In a study aiming to characterize early molecular
changes in premalignant lesions of the oral cavity and the
role of tobacco and alcohol consumption or HPV infections,
the global methylation index was found to be 4.28 (95%CI,
4.1, 4.4) in the oral cancer case series. Methylation was
inversely associated with tobacco use (Guerrero-Preston
et al. 2009).
In cancer, abnormal demethylation leads to the loss of
silencing in repetitive elements which are located on
approximately 50% of the human genome, whereas in
normal cells, these repetitive sequences are regulated by
epigenetic silencing. DNA methylation alterations in HNC
and adjacent nontumor tissues was investigated via a
genome-wide microarray approach (Szpakowski et al.
2009). Of the more than 250,000 repetitive elements
probed, between 5% and 8% displayed disease-related
DNA methylation changes. Among the SVA, HERV, LINE-
1P, AluY, and MaLR families, LINE-1 (Richards et al. 2009;
Subbalekha et al. 2009; Smith et al. 2007), SINE (Alu)
(Richards et al. 2009) repetitive elements, and LRE1
(Furniss et al. 2008; Hsiung et al. 2007) showed loss of
DNA methylation in the tumors when compared to matched
normal adjacent tissue. LINE and LRE1 hypomethylation
were more frequently observed in HPV-negative than in
HPV-positive tumors (Richards et al. 2009).
The Runt-related transcription factor 3 (RUNX3) gene
plays a role in the transforming growth factor-beta (TGF-β)-
induced tumor suppression pathway. Although RUNX3 has
been considered as a TSG in some studies (Bae et al. 1995;
Li et al. 2002), it has been shown that the expression level of
RUNX3 in HNSCC tissues are higher than that in normal
oral epithelial tissues due to demethylation (Ginos et al.
2004; Salto-Tellez et al. 2006). Therefore, it has been
suggested that RUNX3 may have an oncogenic role in
HNSCC and its expression may predict malignant behavior
and the effect of chemotherapeutic drugs in HNSCC as a
potential biomarker (Tsunematsu et al. 2009). In contrast to
HNSCC, the RUNX3 gene is underexpressed in OSCC due
to promoter hypermethylation, indicating that RUNX3 plays
an important role in oral carcinogenesis and may be a useful
diagnostic marker and a potential therapeutic target for
OSCC (Gao et al. 2009).
A recent report has shown that the SEPT9, SLC5A8,
FUSSEL18, EBF3, and IRX1 genes which act in the TGF-β
signaling pathway are commonly methylated and down-
regulated in HNC (Bennett et al. 2009). In IP studies, all
these candidate genes were observed to interact with the
components of the TGF-β pathway (Bennett et al. 2008). It
was reported that decreased mitotic activity and increased
apoptosis rates were observed when the SLC5A8, EBF3,
and IRX1 genes are overexpressed.
Recently, HPV-infected HNSCC tumors have been shown
to display higher levels of global DNA methylation. These
tumors were universally methylated irrespective of the clinical
factors and methylation of the FUSSEL18, IRX1, and EBF3
genes were likely corralated with recurrences. Promoter
methylation of the FUSSEL18 and SEPTIN9 genes was
significantly associated with alcohol and tobacco consump-
tion. A trend between HPV16 positivity and methylation of
the IRX1, EBF3, SLC5A8, and SEPT9 genes was noted and
it has been suggested that this gene panel may be used for
the selection of treatment modality (Bennett et al. 2010).
The Transketolase-like 1 (TKTL1) gene is a novel
candidate oncogene, which is hypomethylated in human
HNSCC tumor samples and contributes to HNSCC carci-
nogenesis via aerobic glycolysis and HIF1-α stabilization
(Sun et al. 2010).
Studies of individual genes
Tumor suppressor genes
Significantly higher methylation of the p14ARF gene has
been reported in OSCC compared to normal control tissues,
implying that the methylation status of p14ARF may be an
important determinant in the early diagnosis and treatment
of OSCC (Kordi-Tamandani et al. 2010; Ishida et al. 2005).
Data on the methylation of the p16 gene promoter is not
consistent. The gene has been analyzed individually or in
gene panels but with discordant results. In a study, p16
methylation has been associated with malignant transforma-
tion of oral epithelial dysplasia and was considered a potential
biomarker for the prediction of prognosis of mild or moderate
oral epithelial dysplasia (Cao et al. 2009; Kresty et al. 2002).
High methylation of the p16 promoter region has also been
reported in carcinomas of the tongue and methylation in the
surgical margins were found to increase the risk of local
recurrences 6.3-fold when compared with patients with
negative margins (Sinha et al. 2009). Varying degrees of p16
methylation has been reported in OSCC (Ohta et al. 2009;
Ruesga et al. 2007; Nakahara et al. 2006; Huang et al. 2002;
Yakushiji et al. 2001; Nakahara et al. 2001; Miracca et al.
1999; Riese et al. 1999; El-Naggar et al. 1997; Tao et al. 1997;
González et al. 1997; Reed et al. 1996), in mucoepidermoid
carcinoma (MEC) of the salivary glands (Guo et al. 2007;
Agnese et al. 2006), in HNC (Yalniz et al. 2011; Koscielny et
al. 2007; Ai et al. 2003), and in larynx cancer (Smigiel et al.
2004). Conversely, there is a also a report of low p16
methylation in larynx cancer (Agnese et al. 2006).
DCC is a candidate TSG located on chromosome 18q21.
Hypermethylation of DCC as a mechanism for inactivation
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in HNSCC has been investigated (Carvalho et al. 2006).
The DCC promoter was highly methylated in the tumors
and there was a significant correlation between DCC
promoter region hypermethylation and lack of DCC
expression.
In a study investigating the methylation and expression
levels of the APC and SFRP genes, both genes were highly
methylated in MEC but not in adjacent normal tissue. There
was significant correlation between methylation and low
SFRP1 expression. Methylation of the SFRP1 gene was the
main cause of decreased SFRP1 expression. Beta-catenin
expression was also associated with reduced SFRP1
expression. In addition, both SFRP1 and beta-catenin
expression were associated with tumor grade and stage.
Survival was particularly poor in patients with reduced
SFRP1 and cytoplasmic/nuclear beta-catenin expression. It
has been suggested that detection of SFRP1 expression and
aberrant beta-catenin expression in the cell may be useful
biomarkers of tumor progression and prognosis in patients
with MEC (Lee et al. 2010).
Alterations in TGF-β signaling are common in HNSCC.
Hypermethylation of TGF-β type I receptor (TGFBR-I)
gene was evaluated via MSP and restriction enzyme-
mediated PCR (MSRE). TGFBR-I expression was lost in
83% of the HNSCC tumors and was linked to DNA
hypermethylation of the CpG-rich promoter region in 62%
of the samples (Muñoz-Antonia et al. 2009).
NDRG2 is a candidate TSG involved in oral squamous
cell cancers via the Akt signaling pathway. Reduced
NDRG2 mRNA levels, caused by promoter methylation,
have been reported in most of the OSCC patients and in
several cases of precancerous leukoplakia with dysplasia
(Furuta et al. 2010).
Hypermethylation of the FancB gene has been
observed in sporadic HNSCC tumors (Smith et al.
2010), while methylation of the SYK gene has been
frequently observed in OSCC; the downregulation of SYK
expression due to promoter methylation was associated
with metastasis (Ogane et al. 2009). MGMT gene
methylation is observed in laryngeal cancer (Zhang et al.
2006, 2004) and HNSCC (Zuo et al. 2004), but not in
normal larynx tissue.
The MALT1 gene, responseible for activating nuclear
factor-kappaB in lymphocyte lineages, is located in a
genomic region encoding putative TSG and is expressed
in the nucleus of oral epithelial cells. Absence of expression
due to epigenetic inactivation during tumor progression has
been associated with tumor recurrence and poor patient
survival, suggesting that analysis of MALT1 expression
may be a useful predictive and prognostic marker for
OSCC (Chiba et al. 2009).
In primary OSCC, aberrant methylation of the
RASSF2 gene and a high frequency of ROBO1 methyla-
tion have been reported in early dysplastic lesions of the
head and neck (Imai et al. 2008; Ghosh et al. 2009). A
significant inverse correlation between RASSF1A promoter
methylation and HPV infection in HNSCC has been shown
(Dong et al. 2003).
GALR1 methylation is observed in primary HNSCC
tumors and correlates with decreased GALR1 expression, as
well as increased tumor size, lymph node status, tumor
stage, CCND1 expression, p16 methylation, and survival
(Misawa et al. 2008).
Methylation of the CDH1 gene promoter has been
reported in tongue cancer (Chang et al. 2002), salivary
gland adenoid cystic carcinoma (Zhang et al. 2007a), and
nonmetastatic oral cancer as an early event (De Moraes et
al. 2008; Maeda et al. 2007a; Yeh et al. 2002).
Expression of the RARβ gene has been studied in primary
tissue specimens of different anatomical sites from patients
with HNSCC and a strong correlation was found between
hypermethylation and reduced expression of RARβ2 (Youssef
et al. 2004). In particular, significantly lower hypermethyla-
tion and higher RARβ2 mRNA expression levels when
compared to the tumors located at other sites of the head
and neck were observed in tumors from the hypopharynx
(Olasz et al. 2007) and salivary duct or acinic cell carcinomas
displaying RASSF1 methylation (Williams et al. 2006).
Genes with different functions
CHFR is a putative early mitotic checkpoint gene which causes
a delay in chromosome condensation in response to mitotic
stress. In a study, aberrant promoter methylation of the CHFR
gene was reported in patients with OSCC, while the gene was
methylated minimally in the surrounding normal mucosa and
no methylation was observed in the CHFR promoter in a
healthy cohort (Baba et al. 2009; Toyota et al. 2003).
The HIC1 gene plays a role in the regulation of
transcription. A study using MSP has reported that HIC1
is highly (95%) methylated in HNSCC and reexpression of
the gene was associated with decreased aggressiveness
(Brieger et al. 2010). On the other hand, in a recent study
from our group, no significant methylation of the HIC1
gene was observed in patients with HNC using a more
sensitive technique (Yalniz et al. 2011).
The CYGB gene was first described as an intracellular
globin of unknown function (Burmester et al. 2002). CYGB
downregulation is a key event in the familial cancer
syndrome of the upper aerodigestive tract. Increased
expression of the CYGB gene displays an inverse correla-
tion with promoter methylation and a strong correlation
with tumor hypoxia. It has been consistently associated
with aggressive tumors in oral and oropharyngeal squa-
mous cell carcinoma when compared with histologically
tumor-free surgical margins (Shaw et al. 2009).
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In individual studies, aberrant methylation of RB1 (Kishi et
al. 2005) and 14-3-3 sigma (Uchida et al. 2004; Gasco et al.
2002) in salivary gland cancer, Apaf-1 (Huang et al. 2004) and
DAPK (Zhang and Kong 2004) in laryngeal squamous cell
carcinoma, TSC2 (Chakraborty et al. 2008), SFRP1, SFRP2,
SFRP5 (Sogabe et al. 2008), RECK (Long et al. 2008),
EpCAM (Shiah et al. 2009), MTNR1A (Nakamura et al. 2008),
IKKalpha (Maeda et al. 2007b), PRTFDC1 (Suzuki et al.
2007), LRP1B (Nakagawa et al. 2006), DBCCR1 (Gao et al.
2004), and 14-3-3 sigma (Gasco et al. 2002) in OSCC,
PGP9.5 (Tokumaru et al. 2008), C/EBPalpha (Bennett et al.
2007), LHX6 (Estécio et al. 2006), STAT1 (Xi et al. 2006),
TIG1 (Tokumaru et al. 2005), TCF21 (Smith et al. 2006),
SOCS3 (Weber et al. 2005), p15 (Chang et al. 2004), and ATM
(Ai et al. 2004) genes in patients with HNC have also been
reported.
miR-137 plays an important role in the cell cycle control.
It has been shown that miR-137 and miR-193a are
epigenetically silenced during oral carcinogenesis (Kozaki
et al. 2008). Methylation of miR-137 has been reported in
squamous cell carcinoma tissue and oral rinse samples and
was associated with gender and inversely associated with
body mass index (Langevin et al. 2010).
Specific lysine residues in histone tails are methylated,
providing an epigenetic marker that modulates biological
functions changing the heterochromatin structure and
leading to tumor development. H3K4 histone methylation
was investigated in OSCC, dysplastic lesions, and normal
tissue samples (Piyathilake et al. 2005). The levels of
H3K4me2 and H3K4me3 displayed striking variations in
OSCC when compared with normal tissue and leukopla-
kias. The me2 levels were increased while the me3 levels
decreased in the tumors (Mancuso et al. 2009).
Nasopharyngeal carcinoma and studies
of TSG gene panels
Nasopharyngeal carcinoma (NPC) is a rare malignancy with
unique genetic, viral, and environmental characteristics that
distinguish it from other types of head and neck carcinoma. It
has a different etiology, epidemiology, prognosis, and therapy.
The clinical management of NPC remains challenging largely
due to the lack of early detection strategies for this tumor
(Loyo et al. 2011; Razak et al. 2010).
A recent study investigating a panel of 18 marker genes in
nasopharyngeal tumors has shown that the methylation status
of the AIM1, APC, CALCA, DCC, DLEC, DLC1, ESR, FHIT,
KIF1A, and PGP9.5 genes were significantly associated with
NPC when compared with other tumors or the benign
nasopharyngeal biopsy samples (Loyo et al. 2011).
In an 11-gene panel, promoter methylation levels of
CDH1, p15, THBS1, RASSF1A, MLH1, MGMT, p16, and
TP73 genes were significantly higher in the tumor samples
from patients with NPC when compared with the lympho-
cytes from the same individuals (Wong et al. 2003a).
Using the discovery approach after expression profiling
among eight potential candidate TSG, promoter methylation of
only three genes (CCNA1, RARRES1, and HRASLS) have been
significantly associated with NPC (Yanatatsaneejit et al. 2008).
Promoter methylation of the RASSF1A, DAPK, and RARβ2
genes was analyzed by MSP in primary NPC tumors and
normal nasopharyngeal epithelia. All genes were highly
methylated in tumor tissue, whereas methylation was not
observed in the normal nasopharyngeal tissue. Methylation of
the three genes was significantly associated with lymph node
involvement. RASSF1A and RARβ2 methylation also correlat-
ed with age at diagnosis, T stage, and histological type (Fendri
et al. 2009). Epigenetic silencing of cellular retinol-binding
proteins, CRBPI, CRBPIV, and RARβ2 are also commonly
observed in NPC tumor samples (Kwong et al. 2005a, 2002).
High methylation frequencies for the DAPK, RASSF1A,
CDH1, and p16 genes are frequently observed in NPC
tumors (Kwong et al. 2002; Chang et al. 2003a). In contrast
to HNSCC (Dikshit et al. 2007), in NPC, no change has
been reported in the RUNX3 promoter region, whereas the
p16, RASSF1A, CDH1, and hMLH1 gene promoters were
frequently methylated (Tan et al. 2006).
In the patients with NPC from Southeast Asia but not from
North Africa, methylation of p16, DLEC1, BLU, and CDH1
genes were found to be associated with the juvenile and adult
forms of the disease. Strong correlations were observed
between aberrant promoter methylation of the CDH1 and
BLU genes and lymph node invasion (Li et al. 2003a, b) or
undifferentiated tumors, respectively (Ayadi et al. 2008).
Single-gene studies in NPC
Tumor suppressor genes
WIF1 is a highly conserved gene on chromosome 12 and
encodes a protein of the sFRP family, which inhibits the
Wnt signaling pathway (Kawano and Kypta 2003). Inhibi-
tion of Wnt signaling induces apoptosis and inhibits tumor
growth in many cancer types (He et al. 2004). Silencing of
the WIF1 gene by hypermethylation may result in the
activation of some tumors (Suzuki et al. 2004; Caldwell et
al. 2004; Ai et al. 2006; Taniguchi et al. 2005). The WIF1
promoter region is highly methylated in nasopharyngeal
tumors, whereas no methylation is observed in the normal
mucosa (Fendri et al. 2010; Chan et al. 2007). WIF1
methylation has been found to be associated with tumor
size, node involvement and metastasis, and age (Fendri
et al. 2010).
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Expression of the MIPOL1 gene is also downregulated
in some NPC tumors via promoter hypermethylation and
allelic loss (Cheung et al. 2009). Likewise, DAB2 is
frequently methylated in NPC, which correlates with the
loss of expression in NPC tumors (Tong et al. 2010).
Two studies investigating the RASSF1A gene have
shown that the gene is highly methylated in primary NPC
but not in normal nasopharyngeal epithelia (Wang et al.
2009; Lo et al. 2001). It has been suggested that aberrant
hypermethylation of RASSF1A and high Epstein–Barr virus
(EBV) load may play an important role in NPC carcino-
genesis (Zhou et al. 2005).
Methylation of CDH1 is more frequently observed in
advanced stages of NPC (Niemhom et al. 2008). Hyper-
methylation of CDH1 promoter and presence of EBV are
predominantly detected in undifferentiated and nonkerati-
nizing NPC compared to squamous cell NPC. Most of the
NPC samples demonstrating CDH1 hypermethylation were
EBV-positive, whereas the EBV genome and hypermethy-
lation were not detected in normal nasopharyngeal tissue
when CDH1 meythylation was absent, indicating a corre-
lation between CDH1 hypermethylation and EBV infection
(Niemhom et al. 2008; Krishna et al. 2005; Li et al. 2003a,
b; Tsao et al. 2003; Kao et al. 2002).
Genes with various funcitons
14-3-3 sigma, the downstream target of p53, is a negative
regulator of cell cycle G2–M phase checkpoint in response
to DNA damage. By MSP, 100% methylation of 14-3-3
sigma was shown in tumor tissue but not in any of adjacent
normal nasopharyngeal epithelial tissue (Yi et al. 2009).
Analysis by real-time PCR, Western blotting, and immuno-
histochemistry have revealed that 14-3-3 sigma expression is
downregulated or absent in NPC samples displaying high
methylation. In addition, hypermethylation of 14-3-3 sigma
has been associated with lymph node and distant metastasis.
Methylation of the PGP9.5 gene is frequently detected in
primary NPC but only minimally observed in normal
nasopharyngeal tissue, indicating that the methylation-
mediated silencing of PGP9.5 may be important in
nasopharyngeal carcinogenesis (Li et al. 2010). The
EDNRB gene, located on chromosome 13q22, was highly
methylated in primary NPC tumor samples, while no
methylation was observed in normal nasopharyngeal
epithelia (Zhou et al. 2007; Lo et al. 2002). In patients
with NPC, high methylation of the LARS2 gene, which is
located at the chromosome 3 common eliminated region-1
(C3CER1) on 3p21.3, has been reported (Zhou et al. 2009).
Several genes which have been studied in gene panels
were also evaluated in single-gene studies. RASFF2 (Zhang
et al. 2007b), DLC1 (Seng et al. 2007), DAPK (Kong et al.
2006; Wong et al. 2002), CHFR (Cheung et al. 2005), TIG1
(Kwong et al. 2005b), BLU (Qiu et al. 2004; Liu et al.
2003a, b), and p16 (Lo et al. 1996) are among those. The
corresponding data are given in Table 3. Other newly
identified TSG are IRF8 (Lee et al. 2008), ADAMTS18,
which is a novel gene located on 16q23 (Jin et al. 2007),
LTF (Yi et al. 2006), CDH13 (Sun et al. 2007), PCDH10
(Ying et al. 2006), TSLC1 (Hui et al. 2003), HIN-1 (Wong
et al. 2003b), and RIZ1 (Chang et al. 2003b) The GNAT1
gene has been shown to be methylated not only in all
primary NPC tissues but also in 80% of tissue samples with
chronic nasopharyngitis (Yi et al. 2007).
Conclusions
Biomarkers predicting clinical response, tumor recurrence,
or patient survival are not available for HNC. Further
studies are needed to identify new biomarkers for early
detection and prediction of the therapeutic response or
prognosis. Follow-up studies using quantitative MSP
analysis, global methylation profiling, and detailed analysis
of downstream DNA repair genes regulated by promoter
methylation may provide new insight into the issue.
Considering the great heterogeneity of HNC, a combination
of multiple genes for analysis may provide a higher
coverage for diverse tumors than the analysis of a single
gene (Carvalho et al. 2008). Recent data indicate that
promoter hypermethylation of the KIF1A and EDNRB
genes is a frequent event in primary HNSCC and
combining only the KIF1A and EDNRB genes provides a
higher specificity and sensitivity than using a panel of 10
different genes (Demokan et al. 2010). Preferential meth-
ylation of these genes in salivary rinses from HNSCC
patients may provide a promising potential biomarker for
the disease. Other genes investigated frequently and found
to display significant differential methylation are RASSF1A,
DAPK1, MGMT, RARβ, CDH1, hMLH1, and CHFR,
although a wide range of different methylation ratios have
been reported. These variations most probably result from
the differences in the sensitivity of the methods, variations
in the processing of the samples, and composition of the
patient cohorts.
Methylation analysis has the additional advantage
that methylation patterns are not affected by external
factors or temporary physiological changes. They persist
and are usually increased during disease progression.
The higher specificity and sensitivity provides a suitable
tool to obtain predictive or prognostic information. So
far, the information about DNA methylation has not
translated into useful and reliable markers for HNC in
the clinical practice. However, given the sensitive and
high-throughput quantitative methodologies for methyl-
ation analysis, specific markers for HNC will certainly
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emerge by careful evaluation and combination of
different marker panels to achieve a high sensitivity
for the disease. Over the next years, clinical tests based
on diagnostic and therapeutic methylation markers will
certainly be available and will be used for the
assessment of prognosis, treatment planning, and to
predict the response.
Future studies aiming to determine the causative role
and significance of these epigenetic alterations may
provide important clues into the mechanism and contri-
bution of the specific events and help to establish a
sequence of methylation events during tumor develop-
ment associated with different stages of head and neck
carcinogenesis. Since tumor-specific DNA can be easily
detected in blood, serum, and saliva, methylation
analysis can be used as an noninvasive method for the
early detection using a panel of the genes specific for
the disease. Furthermore, epigenetic silencing of the
genes offers new therapeutic approaches using demethy-
lating agents. Analysis of genome-wide methylation
profiles by new high-throughput technologies which
enable simultaneous analysis of thousands of genetic
loci will certainly help to identify highly specific novel
methylation biomarkers.
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